LLNL领导AI项目DeNOVO,以加速抗体设计,加快治疗速度。 LLNL leads AI project DeNOVO to accelerate antibody design for faster medical treatments.

Lawrence Livermore国家实验室(LLNL)正在领导一个名为DeNOVO的项目,该项目利用AI将治疗的抗体设计革命化。 The Lawrence Livermore National Laboratory (LLNL) is leading a project called DeNOVO, which uses AI to revolutionize antibody design for medical treatments. 这一倡议得到机构间协议的支持,旨在提高药物发现的效率。 This initiative, supported by an interagency agreement, aims to enhance drug discovery efficiency. DeNOVO将使用人工智能和高性能计算来开发新的抗体设计和定性方法,有可能加速发现有效的医疗方法。 DeNOVO will use AI and high-performance computing to develop new methods for antibody design and characterization, potentially speeding up the discovery of effective medical treatments.